Information Provided By: 
Fly News Breaks for April 19, 2017
IMGN
Apr 19, 2017 | 08:02 EDT
Leerink analyst Michael Schmidt upgraded ImmunoGen to Outperform from Market Perform based on his higher level of conviction on lead asset mirvetuximab soravtansine providing an attractive risk/reward in context of the stock's current valuation. The analyst also raised his price target on the shares to $8 from $2.
News For IMGN From the Last 2 Days
There are no results for your query IMGN
